A Long-term Extension Study of Mirikizumab (LY3074828) in Participants With Crohn's Disease

Inclusion Criteria:

• Participants must have completed study I6T-MC-AMAG (NCT02891226) or studyI6T-MC-AMAM (NCT03926130)

• If female, participant must meet the contraception requirements

Exclusion Criteria:

• Participants must not have developed a new condition, including cancer in theprevious study (I6T-MC-AMAG or I6T-MC-AMAM) that would pose an unacceptable risk inthe trial.

• Participants must not have any important infections including, but not limited to,hepatitis B, hepatitis C, HIV/AIDS, and active tuberculosis (TB) during eitherprevious study.

Note: Participants with a history of active TB with documentation of treatment by the Centers for Disease Control (CDC) and/or World Health Organization (WHO) criteria prior to the originator study are not excluded from the study.

• Participants must not have a known hypersensitivity to any component of mirikizumabor have experienced acute systemic hypersensitivity event with previous study drugadministration in the originating study that precludes mirikizumab therapy.

• Participation must not be pregnant, lactating, or planning to become pregnant whileenrolled in the study or 16 weeks after receiving the last dose of study drug.